Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
18 sept. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...
Adaptive Announces Launch of Epic Integration for clonoSEQ®
13 sept. 2023 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
07 sept. 2023 22h43 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal...
Burning Rock Reports Second Quarter 2023 Financial Results
31 août 2023 01h30 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
12 juin 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas...
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
02 juin 2023 07h34 HE
|
Adaptive Biotechnologies
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of...
Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023
27 avr. 2023 01h01 HE
|
Burning Rock Biotech Limited
GUANGZHOU, China, April 27, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation...
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
12 avr. 2023 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
11 nov. 2021 17h52 HE
|
Adaptive Biotechnologies
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain...
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
30 sept. 2021 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...